IL-37 inhibits the production of inflammatory cytokines in peripheral blood mononuclear cells of patients with systemic lupus erythematosus: its correlation with disease activity

Journal of Translational Medicine

Zhong Huang²  Jing Du³  Liping Ding²  Jinshun Zhang²  Bingni Chen²  Ting Yu²  Yanqun Li²  Dongsheng Hu¹  Yanfei Zhou²  Zhongyang Wen²  Ling Ji³  Liang Ye² 

[1] Department of Preventive Medicine, Shenzhen University School of Medicine, 518060 Shenzhen, China;Shenzhen City Shenzhen University Immunodiagnostic Technology Platforms, 518060 Shenzhen, China;Department of laboratory medicine, Peking University Shenzhen Hospital, 518036 Shenzhen, China

关键词: Peripheral blood mononuclear cell;    Cytokines;    Autoimmunity;    Systemic lupus erythematosus;    Interleukin-37;   

Others  :  817649
DOI  :  10.1186/1479-5876-12-69

 received in 2013-10-19, accepted in 2014-03-12,  发布年份 2014

【 摘 要 】

Background

Interleukin-37 (IL-37), a new member of IL-1 family cytokine, is recently identified as a natural inhibitor of innate immunity. This study aimed to measure the peripheral blood mononuclear cells (PBMCs) and serum levels of IL-37 in patients with systemic lupus erythematosus (SLE) and to investigate its role in SLE, including its correlation with disease activity, organ disorder and the regulation of inflammatory cytokines.

Methods

The expressions of IL-37 mRNAs in PBMCs and serum IL-37 levels in 66 SLE patients were measured by real-time polymerase chain reaction (RT-PCR) and enzyme-linked immunosorbent assay (ELISA). SLE patients PBMCs were stimulated with recombinant IL-37, levels of cytokines TNF-α, IL-1β, IL-6 and IL-10 were detected by RT-PCR and ELISA.

Results

IL-37 mRNAs and serum protein levels were higher in patients with SLE compared with healthy controls. Patients with active disease showed higher IL-37 mRNAs and serum protein levels compared with those with inactive disease as well as healthy controls. Serum IL-37 levels correlated with SLEDAI and inversely with C3 and C4. Serum IL-37 levels were higher in SLE patients with renal involvement compared with those without renal disease. In vitro, IL-37 inhibited the production of TNF-α, IL-1β and IL-6 in PBMCs of patients with SLE, whereas the production of IL-10 was unaffected.

Conclusions

IL-37 associated with SLE disease activity, especially related with SLE renal disease activity. IL-37 is an important cytokine in the control of SLE pathogenesis by suppressing the production of inflammatory cytokines. Thus, IL-37 may provide a novel research target for the pathogenesis and therapy of SLE.

【 授权许可】

   
2014 Ye et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

Figure 4.

Figure 5.

【 参考文献 】

• [1]Akdis M, Burgler S, Crameri R, Eiwegger T, Fujita H, Gomez E, Klunker S, Meyer N, O'Mahony L, Palomares O, Rhyner C, Ouaked N, Schaffartzik A, Van De Veen W, Zeller S, Zimmermann M, Akdis CA: Interleukins, from 1 to 37, and interferon-γ: receptors, functions, and roles in diseases. J Allergy Clin Immunol 2011, 127:701-721.
• [2]Boraschi D, Lucchesi D, Hainzl S, Leitner M, Maier E, Mangelberger D, Oostingh GJ, Pfaller T, Pixner C, Posselt G, Italiani P, Nold MF, Nold-Petry CA, Bufler P, Dinarello CA: IL-37: a new anti-inflammatory cytokine of the IL-1 family. Eur Cytokine Netw 2011, 22:127-147.
• [3]Dinarello C, Arend W, Sims J, Smith D, Blumberg H, O'Neill L, Goldbach-Mansky R, Pizarro T, Hoffman H, Bufler P, Nold M, Ghezzi P, Mantovani A, Garlanda C, Boraschi D, Rubartelli A, Netea M, van der Meer J, Joosten L, Mandrup-Poulsen T, Donath M, Lewis E, Pfeilschifter J, Martin M, Kracht M, Muehl H, Novick D, Lukic M, Conti B, Solinger A, Kelk P, van de Veerdonk F, Gabel C: IL-1 family nomenclature. Nat Immunol 2010, 11:973.
• [4]Nold MF, Nold-Petry CA, Zepp JA, Palmer BE, Bufler P, Dinarello CA: IL-37 is a fundamental inhibitor of innate immunity. Nat Immunol 2010, 11:1014-1022.
• [5]Bufler P, Gamboni-Robertson F, Azam T, Kim SH, Dinarello CA: Interleukin-1 homologues IL-1F7b and IL-18 contain functional mRNA instability elements within the coding region responsive to lipopolysaccharide. Biochem J 2004, 381:503-510.
• [6]McNamee EN, Masterson JC, Jedlicka P, McManus M, Grenz A, Collins CB, Nold MF, Nold-Petry C, Bufler P, Dinarello CA, Rivera-Nieves J: Interleukin 37 expression protects mice from colitis. Proc Natl Acad Sci U S A 2011, 108:16711-16716.
• [7]Sakai N, Van Sweringen HL, Belizaire RM, Quillin RC, Schuster R, Blanchard J, Burns JM, Tevar AD, Edwards MJ, Lentsch AB: Interleukin-37 reduces liver inflammatory injury via effects on hepatocytes and non-parenchymal cells. J Gastroenterol Hepatol 2012, 27:1609-1616.
• [8]Ballak DB, Suzhao L, Janna AVD, Alexander RM, Henry J, Anneke H, Gert-Jan G, Philip B, Sander K, Leo ABJ, Herbert T, Charles AD, Mihai GN, Cees JT, Rinke S: IL-37 protects against obesity-induced inflammation and insulin resistance. Cytokine 2013, 63:245-246.
• [9]Imaeda H, Takahashi K, Fujimoto T, Kasumi E, Ban H, Bamba S, Sonoda H, Shimizu T, Fujiyam Y, Andoh A: Epithelial expression of interleukin-37b in inflammatory bowel disease. Clin Exp Immunol 2013, 172:410-416.
• [10]Crispín JC, Liossis S-NC, Kis-Toth K, Lieberman LA, Kyttaris VC, Juang YT, Tsokos GC: Pathogenesis of human systemic lupus erythematosus: recent advances. Trends Mol Med 2010, 16:47-57.
• [11]Jacob N, Stohl W: Cytokine disturbances in systemic lupus erythematosus. Arthritis Res Ther 2011, 13:228. BioMed Central Full Text
• [12]Su DL, Lu ZM, Shen MN, Li X, Sun LY: Roles of pro- and anti-inflammatory cytokines in the pathogenesis of SLE. J Biomed Biotechnol 2012, 2012:347141.
• [13]Bezalel S, Asher I, Elbirt D, Sthoeger ZM: Novel biological treatments for systemic lupus erythematosus: current and future modalities. Isr Med Assoc J 2012, 14:508-514.
• [14]Song L, Qiu F, Fan Y, Ding F, Liu H, Shu Q, Liu W, Li X: Glucocorticoid regulates interleukin-37 in systemic lupus erythematosus. J Clin Immunol 2013, 33:111-117.
• [15]Hochberg MC: Updating the American College of Rheumatology revised criteria for the classification ofsystemic lupus erythematosus. Arthritis Rheum 1997, 40:1725.
• [16]Bombardier C, Gladman DD, Urowitz MB, Caron D, Chang CH: Derivation of the SLEDAI. A disease activity index for lupus patients. Arthritis Rheum 1992, 35:630-640.
• [17]Wu Q, Yang Q, Lourenco E, Sun H, Zhang Y: Interferon-lambda1 induces peripheral blood mononuclear cell-derived chemokines secretion in patients with systemic lupus erythematosus: its correlation with disease activity. Arthritis Res Ther 2011, 13:R88. BioMed Central Full Text
• [18]Novick D, Elbirt D, Miller G, Dinarello CA, Rubinstein M, Sthoeger ZM: High circulating levels of free interleukin-18 in patients with active SLE in the presence of elevated levels of interleukin-18 binding protein. J Autoimmun 2010, 34:121-126.
• [19]Yu SL, Kuan WP, Wong CK, Li EK, Tam LS: Immunopathological roles of cytokines, chemokines, signaling molecules, and pattern-recognition receptors in systemic lupus erythematosus. Clin Dev Immunol 2012, 2012:715190.
• [20]Apostolidis SA, Lieberman LA, Kis-Toth K, Crispín JC, Tsokos GC: The dysregulation of cytokine networks in systemic lupus erythematosus. J Interferon Cytokines Res 2011, 31:769-779.
• [21]Tsai C-Y, Wu T-H, Yu C-L, Lu J-Y, Tsai Y-Y: Increased excretions of β2-microglobulin, IL-6, and IL-8 and decreased excretion of Tamm-Horsfall glycoprotein in urine of patients with active lupus nephritis . Nephron 2000, 85:207-214.
• [22]Herrera-Esparza R, Barbosa-Cisneros O, Villalobos-Hurtado R, Avalos-Díaz E: Renal expression of IL-6 and TNFα genes in lupus nephritis. Lupus 1998, 7:154-158.
• [23]Uppal SS, Hayat SJ, Raghupathy R: Efficacy and safety of infliximab in active SLE: a pilot study. Lupus 2009, 18:690-697.
• [24]Ostendorf B, Iking-Konert C, Kurz K, Jung G, Sander O, Schneider M: Preliminary results of safety and efficacy of the interleukin 1 receptor antagonist anakinra in patients with severe lupus arthritis. Ann Rheum Dis 2005, 64:630-633.
• [25]Illei GG, Shirota Y, Yarboro CH, Daruwalla J, Tackey E, Takada K, Fleisher T, Balow JE, Lipsky PE: Tocilizumab in systemic lupus erythematosus: data on safety, preliminary efficacy, and impact on circulating plasma cells from an open-label phase I dosage-escalation study. Arthritis Rheum 2010, 62:542-552.
• [26]Llorente L, Weiping Z, Yves L, Yvonne RP, John W, Jorge AV, Brigitte MF, Jean CB, Donato AS, Pierre G, Dominique E: Role of interleukin 10 in the B lymphocyte hyperactivity and autoantibody production of human systemic lupus erythematosus. J Exp Med 1995, 181:839-844.
• [27]Wong CK, Wong PTY, Tam LS, Li EK, Chen DP, Lam CWK: Activation profile of intracellular mitogen-activated protein kinases in peripheral lymphocytes of patients with systemic lupus erythematosus. J Clin Immunol 2009, 29:738-746.
• [28]Thalhamer T, McGrath MA, Harnett MM: MAPKs and their relevance to arthritis and inflammation. Rheumatology 2008, 47:409-414.
• [29]Iwata Y, Wada T, Furuichi K, Sakai N, Matsushima K, Yokoyama H, Kobayashi K: p38 Mitogen-activated protein kinase contributes to autoimmune renal injury in MRL-Fas lpr mice. J Am Soc Nephrol 2003, 14:57-67.